Loading
Scilex Holding Co Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SHAH JAISIM, was filed 18 Dec 2024.
Scilex Holding Co: what insiders have been doing
Scilex Holding Co is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). Between 22 October 2025 and 22 October 2026, 2 insiders published 4 filings.
The flow runs one way only: 3 sales worth €10.8M, from 1 insider, and no purchase. Scilex Holding Co filed the largest sale, €4.4M, on 30 December 2025.
Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (3,171 companies, median 24 filings), a count of 4 filings is below the norm. Looking back to 2023, when coverage begins, insiders filed 15 purchases and 4 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 30.3 m USD and net income of -374.1 m USD.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
32
Thresholds
n/a
Buy Volume
€328,604
15 ops. · all time
Sell Volume
€11M
4 ops. · all time
Who traded when
BuySaleScilex Holding Co3 sales
Jaisim Shah1 buy
Since the insiders bought
- -6.8%Entry US$9.59 · Close at T+365 US$8.94
- -51.4%Entry US$21.16 · Close at T+365 US$10.27
- -58.5%Entry US$21.14 · Close at T+365 US$8.77
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.53
Analyst consensus
Income statement
RevenueUS$30.3M
Gross profitUS$19.7M65% margin
EBITDA-US$357.9M-1183% margin
Net income-US$358.7M-1185.8% margin
Valuation
Beta1.79
Balance sheet & cash
Market capUS$17.8M
Total debtUS$124.1M
Free Cash FlowUS$3.1M
Profitability & ownership
ROA-105.8%
% insiders11.7%
% institutions8.5%
Last declaration on 7 July 2026
Declarations32 total
500,000 sharesCommon stockSEC:0001193125-26-297858:0
7,310,984 shares@ US$0.655537.5% of flowCommon StockSEC:0001193125-25-337437:1
9,657,300 shares@ US$0.539440.8% of flowCommon StockSEC:0001193125-25-337437:2
3,689,016 shares@ US$0.7509100.0% of flowCommon StockSEC:0001193125-25-337437:0
3,250,000 sharesCommon StockSEC:0000950170-25-008463:0
779,371 sharesCommon StockSEC:0000950170-25-006876:0
5,000,000 sharesCommon StockSEC:0000950170-25-002437:0
30,000 shares@ US$0.466.6% of flowCommon StockSEC:0000950170-24-138066:0
Canonical exit: 18 Mar 2025 (T+90)
8,888 shares@ US$0.93968.8% of flowCommon StockSEC:0000950170-24-119394:0
Canonical exit: 29 Jan 2025 (T+90)
32,000 shares@ US$0.989714.6% of flowCommon StockSEC:0000950170-24-118435:0
Canonical exit: 27 Jan 2025 (T+90)
2,000 shares@ US$0.90100.0% of flowCommon StockSEC:0000950170-24-115450:0
Canonical exit: 15 Jan 2025 (T+90)
5,000 shares@ US$0.957.5% of flowCommon StockSEC:0000950170-24-115629:0
Canonical exit: 16 Jan 2025 (T+90)
20,000 shares@ US$0.949672.7% of flowCommon StockSEC:0000950170-24-115452:0
Canonical exit: 15 Jan 2025 (T+90)
10,000 shares@ US$0.97110.3% of flowCommon StockSEC:0000950170-24-115449:0
Canonical exit: 15 Jan 2025 (T+90)
1,000 shares@ US$0.9941.6% of flowCommon StockSEC:0000950170-24-115630:0
Canonical exit: 16 Jan 2025 (T+90)
30,000 shares@ US$0.991713.7% of flowCommon StockSEC:0000950170-24-115226:0
Canonical exit: 14 Jan 2025 (T+90)
6,700 shares@ US$0.9729.8% of flowCommon StockSEC:0000950170-24-115199:0
Canonical exit: 14 Jan 2025 (T+90)
1,000 shares@ US$1.3758.4% of flowCommon StockSEC:0000950170-24-078116:0
14,000 shares@ US$1.7311.3% of flowCommon StockSEC:0000950170-24-075656:0
5,000 shares@ US$1.4127.3% of flowCommon StockSEC:0000950170-24-075773:0
2,000 shares@ US$1.4113.1% of flowCommon StockSEC:0000950170-24-075674:0
5,000 shares@ US$1.4111.3% of flowCommon StockSEC:0000950170-24-075669:0
6,000 shares@ US$1.419.0% of flowCommon StockSEC:0000950170-24-075213:0
33,333 shares@ US$1.4121.8% of flowCommon StockSEC:0000950170-24-073618:0
56,939 shares@ US$0.91519.3% of flowCommon StockSEC:0000950170-24-061928:1
Canonical exit: 15 Aug 2024 (T+90)
25 of 32 declarations
About Scilex Holding Co
Scilex Holding Co is a company listed on the XNAS market, focused on developing pain management treatments. It aims to provide innovative solutions to enhance patients' quality of life.
